NASDAQ:KDNY

Chinook Therapeutics, Inc Earning Date

USA |NASDAQ |USD

KDNY Earnings Date

|
Report Date Period Ending EPS Forecast Last Quarter's EPS Last Year's EPS
Nov 3, 2021 Sep 2021 $-0.84 $-0.52 $-0.79
Report Date Period Ending Revenue Forecast Last Quarter’s Revenue Last Year’s Revenue
Nov 3, 2021 Sep 2021 $40.00K $34.00K $3.79M

Chinook Therapeutics, Inc's next earnings date is Wednesday, Nov 3, 2021 for the fiscal quarter ending Sep 2021.

KDNY Earnings Date & History Chart

KDNY Earnings & Revenue Forecast

KDNY Earnings Forecast

|
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2021 6 $-0.88 $-1.12 $-0.66
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2021 8 $-3.52 $-4.28 $-3.14
Dec 2022 8 $-3.27 $-4.48 $-2.44

KDNY Earnings Revision Trend

|
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2021 0 / 0 $-0.88 $-0.86 $-0.79
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2021 0 / 0 $-3.52 $-3.41 $-3.20
Dec 2022 0 / 0 $-3.27 $-3.29 $-3.10

KDNY Revenue Forecast

|
Period End # of Analysts Revenue Forecast Low Revenue Forecast High Revenue Forecast
Dec 2021 6 $40.00K $0.00 $250.00K
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2021 8 $530.00K $380.00K $1.00M
Dec 2022 8 $140.00K $0.00 $1.10M

KDNY Earnings Date & Revenue History

KDNY Earnings History

|
Show More
Show More

KDNY Revenue History

|
Show More
Show More

Chinook Therapeutics, Inc Next Earnings Date & Report

KDNY Next Earnings Date & Report Preview: Sep 2021 (FQ)

KDNY's next earnings date is Wednesday, Nov 3, 2021 for the fiscal quarter ending Sep 30, 2021.

According to 6 analysts, the average EPS estimation for Chinook Therapeutics, Inc's next quarterly earnings is $-0.84, with a low EPS estimation of $-1.13, and a high estimation of $-0.63.

Over the last 1 month, EPS estimates have seen 0 upward revisions and 0 downward. The EPS 1 month trend is $-0.84, the last 2 month trend is $-0.83, and the 3 month trend is $-0.76.

Based on 6 analysts, the average revenue estimation is $40.00K, with a low revenue estimation of $0.00, and a high estimation of $250.00K.

Chinook Therapeutics, Inc Previous Earnings Dates & Reports

KDNY Previous Earnings Date & Report Recap: Jun 2021 (FQ)

Chinook Therapeutics, Inc's previous earnings date was Aug 12, 2021 for its fiscal quarter ended Jun 30, 2021.

KDNY's earnings per share (EPS) was $-0.52, beating the consensus analysts forecast of $-0.85 by 37.91%.

The EPS was higher than the previous fiscal quarter (Mar 2021) by -37.51%, and higher than the same period a year before (Jun 2020) by -50.03%.

Revenues were $34.00K.

The company reported a net income of $-42.57M.

Free cash flow for the quarter was $-27.58M , compared to $-15.20M last quarter and $-4.10M a year before.

KDNY ended the quarter with $40.43M in total debt, an increase of 4.44% compared to the previous quarter.

KDNY Previous Earnings Date & Report Recap: Dec 2020 (FY)

Chinook Therapeutics, Inc's previous annual earnings date was Dec 31, 2020 for its fiscal year ended Dec 31, 2020.

KDNY's earnings per share (EPS) was $-3.53, missing the consensus analysts forecast of $-1.74 by 102.97% , and higher than the previous year's EPS (Dec 2019) by -30.75%.

Revenues were $827.00K, worse than the forecast of $22.04M by -96.25%, and down by -95.21% from previous year's revenue.

The company reported a net income of $-81.62M.

Chinook Therapeutics, Inc reported a free cash flow of $-55.89M for its fiscal year, compared to $-14.35M a year ago.

The company ended the fiscal year with $38.71M in total debt. lala